All In Biotech

Drug Trial Radar · NCT06396026

A Study of Efficacy and Safety of TLL-018 in CSU Participants

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TLL-018 in Participants With Moderate-to-Severe Chronic Spontaneous Urticaria With Inadequate Controll to Second Generation H1-antihistamines

Last checked: Nov 19, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 440 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

440

Actual

Start

Mar 27, 2024

Primary completion

Oct 23, 2025

Study completion Dec 30, 2026

Sponsor

Sponsor type
Industry
First posted
May 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TLL-018 in Participants With Moderate-to-Severe Chronic Spontaneous Urticaria (CSU) With Inadequate Controll to Second Generation H1-antihistamines.

Conditions

  • Chronic Spontaneous Urticaria

Interventions

  • TLL-018 tabletsDrug

    Oral TLL-018 tablets taken orally 1 pieces BlD for 52 weeks

  • Placebo tabletsDrug

    Oral Placebo tablets taken orally 1 pieces BlD for 12 weeks and then Oral TLL-018 tablets taken orally 1 pieces BlD for 40 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in UAS7 at Week 12Time frame: 12 weeks
  2. Change from baseline in ISS7 at Week 12Time frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.